[ad_1]
London, July 9, 2021 /PRNewswire/ – Benevolent artificial intelligence Announced the appointment of Dr. François Nader as Chairman.
Dr. Nader is an experienced biopharmaceutical executive, currently serving as Chairman of Talaris, Acceleron Pharma, Independent Director of Moderna and Alexion, and Senior Advisor of Blackstone Life Sciences. After a remarkable career, Dr. Nader’s most recent operational position was as President, CEO and Executive Director of NPS Pharma from 2008 to 2015, before finally selling it to Shire.
Joanna ShieldsBenevolentAI CEO and Director of the Board of Directors commented: “Dr. François Nader has brought a wealth of expertise in late-stage, high-growth to our board. After an important year of pipeline progress and continuous AI platform verification, we are ready to enter the next stage. A stage of growth to deliver new medicines at speed and scale. We welcome François’ vision and commitment to develop purposeful and defined categories of business.”
Dr. François Nader commented: “Benevolent is due to its innovative computing R&D platform and focus on…
The full story on Benzinga.com
[ad_2]
Source link
